Skip to main content
DONG-A ST CO.,LTD logo

DONG-A ST CO.,LTD — Investor Relations & Filings

Ticker · 170900 ISIN · KR7170900005 KO Manufacturing
Open in API
Filings indexed 634 across all filing types
Latest filing 2026-03-13 Regulatory Filings
Country KR South Korea
Listing KO 170900

About DONG-A ST CO.,LTD

https://www.donga-st.com

Dong-A ST CO., LTD. is a pharmaceutical company focused on the research, development, manufacturing, and marketing of ethical drugs, medical devices, and diagnostics. The company's portfolio includes proprietary new drugs such as Stillen (gastritis), Zydena (erectile dysfunction), and Motilitone (functional dyspepsia). Operating from cGMP-compliant facilities, it exports a diverse range of products, including novel drugs, generics, and biopharmaceuticals, to global markets. The company maintains a strong commitment to innovative R&D, with a pipeline featuring first-in-class therapeutic candidates for metabolic diseases, including MASH (Metabolic dysfunction-associated steatohepatitis) and obesity, which are being advanced through a dedicated global R&D base.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Dong-A ST regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for domestic product approval of a new diabetes treatment (Sugar-Empa Tablet). This is a standard corporate disclosure filed with the Korea Exchange (KRX) to inform investors of significant business developments, such as clinical trial results and regulatory filings. Since it does not fit into specific categories like financial reports, dividends, or board changes, it falls under the general regulatory filing category.
2026-03-13 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Dong-A ST regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for domestic product approval of a new diabetes treatment (Suganova Extended Release Tablet). It details the clinical trial results, regulatory submission date, and expected effects. Since this is a formal regulatory disclosure of a material business event (filing for drug approval) that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2026-03-13 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 95% confidence The document is a 'Report of Changes in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) for Dong-A ST. It details specific transactions (purchases and sales) made by directors, executives, and related entities (foundations). This type of filing is a standard regulatory requirement for reporting insider trading and changes in major shareholdings. In the provided taxonomy, 'Director's Dealing' (DIRS) is the most accurate category for reports detailing personal share transactions by company directors and executives, while 'Major Shareholding Notification' (MRQ) is for significant ownership threshold changes. Given the focus on individual director/executive transactions and the specific nature of the report, 'DIRS' is the most appropriate classification.
2026-03-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings (acquisitions, disposals, and changes in special relationships), and the purpose of holding (influence on management). This corresponds to the 'Major Shareholding Notification' category.
2026-03-06 Korean
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Dong-A ST regarding their 'Compliance Program (CP) Operation Status'. It details the 2025 performance and 2026 plans for their internal compliance and anti-corruption systems. Since this is a specific regulatory announcement regarding corporate governance and compliance practices that does not fit into financial reporting, dividend notices, or management changes, it falls under the 'Regulatory Filings' category as a general disclosure.
2026-02-27 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Dong-A ST Co., Ltd. It outlines the meeting date, location, agenda items (such as approval of financial statements, election of directors, and board remuneration), and instructions for electronic voting. This document is a formal proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.